EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacogenomics: DPYD and Prevention of Toxicity

J Keen, J H McDermott, E Aguilar-Martinez, W G Newman

Clinical Oncology · 2025

DOI: 10.1016/j.clon.2024.103706 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Oncology, 2025. Verfasst von J Keen und 3 weiteren Autor:innen. Beteiligte Einrichtung: NHS North West Genomic Medicine Service Alliance, UK. Electronic address: Jessica.keen@mft.nhs.uk. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Pharmacogenetics, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: NIHR Manchester Biomedical Research Centre, Innovate UK, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2020, the introduction of pre-emptive DPYD genotyping prior to the administration of systemic fluoropyrimidine-based chemotherapy represented one of the first widespread pharmacogenetic testing programmes to be applied nationally in the United Kingdom. Pharmacogenetic variants in the DPYD gene found in between 3 and 6% of the population are a recognised cause of primary DPD enzyme deficiency and associated increased risk of severe fluoropyrimidine toxicity [1]. Yet, the availability of testing globally is heterogeneous. Despite growing evidence that in addition to reducing drug-induced toxicity, DPYD-guided dosing does not negatively affect outcomes, further research on the impact of routine DPYD genotyping in the UK population is required. With mandatory testing in the UK focussed on four well-characterised variants, there is a need to address the applicability of this strategy across diverse ethnic or ancestral populations. We highlight approaches to identify and characterise rare variants in DPYD and in other genes involved in the pyrimidine metabolic pathway to reduce healthcare inequalities. Finally, we discuss the future of pharmacogenomics within cancer care, and the potential to harness innovative digital and genotyping technologies to streamline prescribing and optimise both systemic anti-cancer therapies and supportive care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)PharmacogeneticsNeoplasmsHumans

Stichwörter der Autor:innen

DPYDfluoropyrimidineinteroperabilitypersonalised medicinepharmacogeneticspharmacogenomicstoxicity

Substanzen

Dihydrouracil Dehydrogenase (NADP)

Autor:innen und Institutionen

  • NHS North West Genomic Medicine Service Alliance, UK. Electronic address: Jessica.keen@mft.nhs.uk.
  • Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK; The Division of Evolution, Infection and Genomics, School of Biological Sciences, University of Man…
  • The Division of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, UK.
  • NHS North West Genomic Medicine Service Alliance, UK; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK; The Division of Evolution, Infection and Geno…

Förderung

  • NIHR Manchester Biomedical Research Centre
  • Innovate UK
  • National Institute for Health and Care Research

Zitieren

APA

Keen, J., McDermott, J. H., Aguilar-Martinez, E., & Newman, W. G. (2025). Pharmacogenomics: DPYD and Prevention of Toxicity. Clinical Oncology. https://doi.org/10.1016/j.clon.2024.103706

Vancouver

Keen J, McDermott JH, Aguilar-Martinez E, Newman WG. Pharmacogenomics: DPYD and Prevention of Toxicity. Clinical Oncology. 2025. doi:10.1016/j.clon.2024.103706

BibTeX
@article{Keen2025,
  author = {Keen, J and McDermott, J H and Aguilar-Martinez, E and Newman, W G},
  title = {Pharmacogenomics: DPYD and Prevention of Toxicity},
  journal = {Clinical Oncology},
  year = {2025},
  doi = {10.1016/j.clon.2024.103706}
}
Kostenlos starten →